Literature DB >> 12468276

High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002.

Caroline Bernegger1, Nenad Blau.   

Abstract

Tetrahydrobiopterin (BH(4))-responsive hyperphenylalaninemia (HPA) is a recently described variant of phenylalanine hydroxylase deficiency. In contrast to patients with classical phenylketonuria, these patients respond to BH(4) loading tests (20mg/kg) with decrease of plasma phenylalanine levels 4 and 8 h after administration and they can be treated with BH(4) monotherapy. We retrospectively evaluated 1,919 loading tests from 33 different countries performed in our laboratory between 1988 and 2002 of which 278 loading tests were performed with 6R-BH(4), which is about 33% more active than the formerly used 6R,S-BH(4). The loading tests were performed between the ages of one week and 4.6 years, using 2.6-30.0 mg 6R,S- or 6R-BH(4)/kg. Plasma phenylalanine levels before the test ranged from 121 to 4,705 micromol/L. We calculated the phenylalanine "hydroxylation rate" 4 and 8 h after BH(4) administration and plotted the slope of the hydroxylation rate against the phenylalanine levels at time 0. The slope was greater than 3.75 in 65, 74, 33, 17, 0, and 10% of patients with basal phenylalanine levels of 120-400, 400-800, 800-1,200, 1,200-1,600, 1,600-2,200, and >2,200 micromol/L, respectively, when loaded with 20 mg 6R-BH(4)/kg (p>0.0001). This is 5-20 times higher compared with tests using 6R,S-BH(4) or lower doses of BH(4). More than 70% of patients with mild HPA (<800 micromol/L) are found to be BH(4) responders. Therapy with BH(4) (approximately 10mg/kg/day) was initiated in several patients instead of a low-phenylalanine diet, resulting in much better treatment compliance. Our data further demonstrate that BH(4) loading tests can only distinguish between BH(4) responders and non-responders. To differentiate between BH(4) and phenylalanine hydroxylase deficiencies additional tests are essential.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468276     DOI: 10.1016/s1096-7192(02)00171-3

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  35 in total

Review 1.  Phenylketonuria: a 21st century perspective.

Authors:  Francjan J van Spronsen
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

2.  Severe mucitis after sublingual administration of tetrahydrobiopterin in a patient with tetrahydrobiopterin-responsive phenylketonuria.

Authors:  Thomas Opladen; Marcel Zurflüh; Ilse Kern; Lucja Kierat; Beat Thöny; Nenad Blau
Journal:  Eur J Pediatr       Date:  2005-02-22       Impact factor: 3.183

3.  Chaperone-like therapy with tetrahydrobiopterin in clinical trials for phenylketonuria: is genotype a predictor of response?

Authors:  Christineh N Sarkissian; Alejandra Gamez; Patrick Scott; Jerome Dauvillier; Alejandro Dorenbaum; Charles R Scriver; Raymond C Stevens
Journal:  JIMD Rep       Date:  2011-12-06

Review 4.  Sapropterin dihydrochloride for phenylketonuria.

Authors:  Usha Rani Somaraju; Marcus Merrin
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

Review 5.  Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.

Authors:  Ania C Muntau; João Leandro; Michael Staudigl; Felix Mayer; Søren W Gersting
Journal:  J Inherit Metab Dis       Date:  2014-04-01       Impact factor: 4.982

6.  Linking genotypes database with locus-specific database and genotype-phenotype correlation in phenylketonuria.

Authors:  Sarah Wettstein; Jarl Underhaug; Belen Perez; Brian D Marsden; Wyatt W Yue; Aurora Martinez; Nenad Blau
Journal:  Eur J Hum Genet       Date:  2014-06-18       Impact factor: 4.246

Review 7.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

8.  Utility of phenylalanine hydroxylase genotype for tetrahydrobiopterin responsiveness classification in patients with phenylketonuria.

Authors:  Meghan E Quirk; Steven F Dobrowolski; Benjamin E Nelson; Bradford Coffee; Rani H Singh
Journal:  Mol Genet Metab       Date:  2012-07-20       Impact factor: 4.797

9.  Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: assessing responsiveness in a model of statistical process control.

Authors:  M Lindner; G Gramer; S F Garbade; P Burgard
Journal:  J Inherit Metab Dis       Date:  2009-06-10       Impact factor: 4.982

10.  New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride.

Authors:  Cary O Harding
Journal:  Biologics       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.